Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02533570 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus
A Phase 2 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02533570 is a Phase 2 study that was terminated before completion, run by Seagen. The registered enrollment target is 20 participants.
The verdict
NCT02533570, a Phase 2 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of brentuximab vedotin in adults with active systemic lupus erythematosus (SLE).
Interventions
- DRUG Placebo
- DRUG Brentuximab vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-06-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02533570
The ClinicalTrials.gov registry entry for NCT02533570 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02533570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02533570 about?
NCT02533570 is a clinical study titled "Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus". The purpose of this study is to evaluate the safety and tolerability of brentuximab vedotin in adults with active systemic lupus erythematosus (SLE).
What is the current status of trial NCT02533570?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2015-07. Estimated completion is 2017-06-05.
What interventions are being tested in trial NCT02533570?
The interventions under investigation include: Placebo (DRUG), Brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT02533570?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.